✦ LIBER ✦

Efficacy of Valganciclovir in the Treatment of Cytomegalovirus Disease in Kidney and Pancreas Transplant Recipients

✍ Scribed by F.L. Luan; P. Chopra; J. Park; S. Norman; D. Cibrik; A. Ojo

Book ID: 116932921
Publisher: Elsevier Science
Year: 2006
Tongue: English
Weight: 77 KB
Volume: 38
Category: Article
ISSN: 0041-1345
DOI: 10.1016/j.transproceed.2006.10.105

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The Efficacy and Safety of 200 Days Valg

The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients

✍ A. Humar; Y. Lebranchu; F. Vincenti; E. A. Blumberg; J. D. Punch; A. P. Limaye; 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 382 KB

Treatment of Cytomegalovirus Infection o

Treatment of Cytomegalovirus Infection or Disease in Solid Organ Transplant Recipients with Valganciclovir

✍ Jacques Fellay; Jean-Pierre Venetz; Manuel Pascual; John-David Aubert; Charles S 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 36 KB

Treatment of Cytomegalovirus Infection o

Treatment of Cytomegalovirus Infection or Disease in Solid Organ Transplant Recipients With Valganciclovir

✍ J. Fellay; J.-P. Venetz; J.-D. Aubert; C. Seydoux; M. Pascual; P.R.A. Meylan 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Efficacy and safety of low-dose valganci

Efficacy and safety of low-dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients

✍ Jeong M. Park; Kathleen D. Lake; Juan D. Arenas; Robert J. Fontana 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 1 views

The efficacy and safety of valganciclovir (VGCV) for cytomegalovirus (CMV) prophylaxis in liver transplant recipients has not been established. We retrospectively compared the efficacy and safety of low-dose oral VGCV (450 mg once daily for 90 days) and standard oral ganciclovir (1 g three times a d

Acyclovir prophylaxis of cytomegalovirus

Acyclovir prophylaxis of cytomegalovirus disease in kidney transplant recipients

✍ A Vila; L.L Guirado; A Balius; M Dı́az; E Baró; M Olaya; M Andrade; I Agraz; R S 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Signs and Symptoms of Cytomegalovirus Di

Signs and Symptoms of Cytomegalovirus Disease in Kidney Transplant Recipients

✍ F. Pour-Reza-Gholi; A. Labibi; F. Farrokhi; M. Nafar; A. Firouzan; B. Einollahi 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 59 KB